A "higher cut-point of PD-L1 expression" is probably necessary for a PD-1 monotherapy to work relative to chemotherapy in first-line non-small-cell lung cancer, medical oncologist Matthew Hellman, of Memorial Sloan Kettering Cancer Center, told BioWorld Today.